RxDoctor Payments Data

Sydney Grabau

Physician Assistant · Amherst, NYNPI 1013323740

Payments from drug & device makers

$14,209in general payments, 2019–2025

Across 700 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • MDD US Operations, LLC$1K
  • UCB, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$671
  • Jazz Pharmaceuticals Inc.$611
  • plus $7K from 48 others

What the payments were for

  • Consulting fees$5854%
  • Food & beverage$13,56995%
  • Education$550%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,209 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$15,138
Medicare patients
23
Services billed
1,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate42$65,747
UbrelvyUbrogepant38$48,967
Emgality PenGalcanezumab-Gnlm25$16,088
QuliptaAtogepant14$14,585
Aimovig AutoinjectorErenumab-Aooe13$8,847
Divalproex Sodium ErDivalproex Sodium22$1,488
Sumatriptan Succinate20$1,028
RizatriptanRizatriptan Benzoate23$370
Baclofen20$301
Gabapentin25$283
Propranolol Hcl25$241
Topiramate23$228
Tizanidine Hcl11$95
Cyclobenzaprine Hcl17$89
Trazodone Hcl12$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$161$65,74742 claims
AbbVieUbrelvy, Qulipta$2,314$63,55252 claims
Upsher-smith Laboratories LLCTopiramate$108$22823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →